MedTrace Logo

n-3 Fatty Acid Infusion and Type 2 Diabetes

NCT00829569 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2011-11-04

No results posted yet for this study

Summary

The purpose of this experimental study is to investigate whether an acute lipid infusion added marine n-3 fatty acids produces effects on insulin sensitivity in subjects with type 2 diabetes, when compared with an acute lipid infusion without marine n-3 fatty acids. Furthermore other effects on intermediary metabolism are tested for.

Conditions

Interventions

DIETARY_SUPPLEMENT

Intralipid +/- Omegaven

Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all. Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions. Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil).

Sponsors & Collaborators

  • Norwegian University of Science and Technology

    collaborator OTHER

  • Norwegian Foundation for Health and Rehabilitation

    collaborator OTHER

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • Norwegian Diabetes Association

    collaborator OTHER

  • St. Olavs Hospital

    lead OTHER

Principal Investigators

  • Valdemar Grill, M.D. · St. Olavs Hospital, NTNU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2004-05-31
Completion
2008-10-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00829569 on ClinicalTrials.gov